KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Change in Account Payables (2016 - 2025)

Ionis Pharmaceuticals has reported Change in Account Payables over the past 13 years, most recently at $13.8 million for Q4 2025.

  • Quarterly results put Change in Account Payables at $13.8 million for Q4 2025, down 60.93% from a year ago — trailing twelve months through Dec 2025 was -$15.4 million (down 196.06% YoY), and the annual figure for FY2025 was -$15.4 million, down 196.06%.
  • Change in Account Payables for Q4 2025 was $13.8 million at Ionis Pharmaceuticals, up from -$8.8 million in the prior quarter.
  • Over the last five years, Change in Account Payables for IONS hit a ceiling of $35.2 million in Q4 2024 and a floor of -$20.4 million in Q2 2025.
  • Median Change in Account Payables over the past 5 years was -$1.0 million (2024), compared with a mean of $192150.0.
  • Biggest five-year swings in Change in Account Payables: tumbled 2428.22% in 2021 and later soared 556.04% in 2023.
  • Ionis Pharmaceuticals' Change in Account Payables stood at $4.7 million in 2021, then tumbled by 195.27% to -$4.5 million in 2022, then soared by 556.04% to $20.6 million in 2023, then soared by 71.06% to $35.2 million in 2024, then crashed by 60.93% to $13.8 million in 2025.
  • The last three reported values for Change in Account Payables were $13.8 million (Q4 2025), -$8.8 million (Q3 2025), and -$20.4 million (Q2 2025) per Business Quant data.